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Introduction: The carcinoembryonic antigen, CEA, is the tumor marker most used in colorectal patients, principally during follow
up after radical surgery. High serum CEA levei before surgery is often associated with worse prognosis, in some studies. Objective:
The purpose of this study was to evaluate the preoperative carcinoembryonic antigen leveis (CEA) and the frequency of recurrence.
Material and Methods: Eighty-three patients with colorectal cancer at Dukes stages A, B or C were evaluated retrospectively.
The patients'follow up was at least two years or to death. CEA was detemined in serum by enzyme immunoassay (Sorin Biomedica),
normal value 0-5ng/ml. Results: Disease recurrence was observed in 32 patients (38.5%), 13 Dukes B and 19 Dukes C. Seventy
five per cent of the patients with CEA higher than 1Ong/ml relapsed and 80% of the patients without recurrence had normal CEA.
Disease recurrence in patients with preoperative elevated CEA occurred during the first year of follow up in 56% of the patients.
Conclusion: Although the tumor stage is today the most valuable prognostic variable in colorectal cancer, the preoperative CEA
value can provide some additional information in the prognosis of the patient.
UNITERMS: CEA. Colorectal cancer. Recurrence.
INTROOUCTION
Colorectal cancer is one of the most common cancersin industrialized cities. In Brazil, it is the 4th largestcause of cancer in women and the 6th in men. In
1995,22000 persons had colorectal cancer and 3000 died
from this cancer in this country.
The carcinoembryonic antigen (CEA), first described
by Gold and Freedman(') in 1965, is a glycoprotein present
in a high number (90%) of colorectal adenocarcinoma.
Serum determination of CEA is the the most widely used
tumor marker in these patients. The main function of this
marker is to detect early recurrence during follow up after
radical surgery. The serum dosage of CEA at diagnosis has
low sensitivity because patients with colorectal cancer can
have normal leveIs of serum CEA. The relationship between
high CEA serum leveIs in the preoperative period and worse
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prognosis has been investigated in several studies2,3,4,5, so
far without definite conclusion. Patients with high CEA
serum leveIs before surgery could have a higher incidence
of recurrence than patients with normal leveIs.
The aim ofthis study was to retrospectively evaluate
the serum CEA leveIs before surgery in operable colorectal
cancer patients as a predictor of recurrence. The possible
relationships between serum leveIs of CEA and sex, age,
diameters of the tumor, histological diffentiation, tumor
site (colon or rectum) and Dukes stage have also been
evaluated.
PATIENTS ANO METHOOS
We retrospectively reviewed 83 patients with
colorectal adenocarcinoma treated at the Gastroenterology
division of the Hospital São Paulo. The mean age of the
patients was 57 years (29-83 years), there being 42 women
and 41 men. 44 had colon cancer and 39 rectal cancer. All
had operable cancer. Staging was performed according to
Dukes' stages (Dukes A in 3, Dukes B in 46 and Dukes C
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Table 2
Number of patients with CEA > or < 5ng/ml according
to the Dukes stage
Table 1
Mean :t epm of CEA serum leveis in Dukes stages.
Dukes A Dukes B Dukes C
X :t epm 1.93 :t 0.88 5.82 :t 1.86 23.6 :t 6.33
Thirty years after its description by Gold and
Freedman(l), the CEA remains the tumor marker most
studied in colorectal cancer, its main function being the
monitoring of patients after the surgical resection of the
tumor. The preoperative CEA leveI as a prognostic index
is not yet defined, although many authors believe that the
CEA leveI offers an additional criterion for evaluating the
prognosis of colorectal cancer.
As in the majority of previous studies(2,4),we also did
not observed any differences of CEA leveIs when comparing
sex, age, tumor site, tumor diameter or histological
differentiation. Carpellan et. al.(6), observed higher CEA
sensitivity leveIs for rectal cancer than for colon cancer,
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had normal CEA serum leveIs (Table 4). The Chi-square
test between the patients with or without recurrence
according to the serum CEA leveIs either normal or elevated,
was statistically different (p= 0.008).
The sensitivity, specificity, the positive predictive
value and the negative predictive value are described in
Table 5.
The frequency of recurrence according to Dukes stage
was 28% for the B stage and 56% for the C stage. In Dukes
stage B, the CEA leveI was elev~ted in 30% of the patients
who developed recurrence, and normal in 82% of patients
without recurrence. In Dukes stage C, 19 patients developed
recurrence, of which 12 (63%) had a CEA leveI greater
than 5ng/mI. Among the other 15 patients without relapse,
10 (67%) had normal serum leveIs. These differences were
not significant by the Chi square test (p>0.05).
in 34). All the patients were folIowed for at least two years
or up to death.
Serum samples were taken preoperatively, within 30
days of surgery and stored at -20°C. Serum leveIs of CEA
were measured by Elisa, using the Sorin Biomedica kit.
Normal values are from 0-5ng/mI. .
We calculated the sensitivity, specificity and positive
and negative predictive value for CEA as an index oftumor
recurrence. Statistical analysis consisted of Kruskal- Wallys
analysis of variance or Chi square test. Significance was
defined as p < 0.05.
RESULTS
The mean and standard mean error of CEA values in
Dukes stages A, B and C were 2 :t 1.96; 5.8 :t 5.82; 23.6 :t
23.59 (Tablel).There was no significant difference with
respect to sex (p=0.94), age before or after 45 years
(p=0.94), cancer site (p=0.77), diameter of the tumor
(p=0.96), or histological differentiation (p=0.87).
The CEA values were differentiated in alI three stages
by the Kruskal-Wallys analysis (p= 0.043), in which
patients with. Dukes stage' A were the same as those with
stage B, but those with stage C were different from both A
and B. Among the 46 patients with Dukes stage B, 9 (34%)
had elevated serum CEA leveis and among the 34 patients
with stage C, 17 (50%) had elevated CEA serum leveI.
The 3 patients with Dukes'stage A had normal serum CEA
leveIs (Table2).
Twenty six patients (31 %) had CEA leveIs greater
than 5ng/ml (Table 2). Disease recurrence was found in
32 patients, 13 Dukes B and 19 Dukes C, 22 had
metastases, most ferquently in the liver (57%), and 10
had local recurrence. CEA leveIs were elevated in 7 of
the 12 patients who developed liver metastases. Before
the completion of 1 year of follow up, 12 patients had
relapsed. Among the 32 patients with recurrence of the
disease during the follow up, 16 had preoperative elevated
CEA serum leveIs and 16 had normal CEA leveIs. In 9 of
the 16 patients with an elevated preoperative CEA, the
recurrence appeared during the first year of follow up,
while in the 16 with normal serum CEA levei the diagnosis
of recurrence was done after 1 year in 81% of the patients
(Table 3). This differenc~ was significant by the Chi square
test (p= 0.04).
Recurrence of the disease was observed in seventy
five per cent of the patients with preoperative CEA leveis
greater than 10ng/ml. On the other hand, among the 51
patients without recurrence during the follow up, 41 (80%)
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Table 3
Number of patients with CEA > or < 5ng/ml and the
time of recurrence
Table 5
Number of patients with CEA > or < 5ng/ml and with
or without recurrence
Time of Recurrence
< 1 year
>1 year
CEA < 5ng/ml
3
13
CEA >5ng/ml
9
7
Recurrence
Without Recurrence
CEA < 5ng/ml CEA >. 5ng/ml
16 16
41 10
attributing these differences to the fact that rectal cancer is
more often infiltrative and annular.
The sensitivity ofCEA at the time of diagnosis ofthe
tumor at Dukes stages A or B was 18%.and 50% at stage
C, which was a result similar to Chu et alO).The mean serum
leveIs were higher for tumors in Dukes stage C than for
stages B or A. The differences in serum CEA were
statistically significant. The CEA leveI differentiated Dukes
stage A from C, and C from B, but not A from B.
We observed, as in previous studies, that 38.5% of
the patients relapsed. This percentage was higher in the
patients with nodal involvement (Dukes C). In this group,
the frequency of recurrence was 58% and the CEA leveI
was elevated in 60% of the patients. The Gastrointestinal
Tumor Study Group(8) reported that patients with 4 or more
nodal involvements and CEA leveI greater than 5ng/ml had
a higher risk of recurrence and decreased survivaI.
CEA preoperative leveIs were normal in 50% of the
patients who developed recurrence and elevated in the
others, and therefore patients with normal serum CEA
leveI can develop recurrence during follow up. The
sensitivity was lower than in the studies of Wang(9) and
Tate(lO)but similar to McCall(\ I). Seventy five per cent of
pittients with CEA leveI higher than 10ng/ml developed
recurrence, but on the other hand, among the 50 patients
without recurrence, the CEA leveI were normal in 80%.
Tsushiya et al(4)observed that patients with preoperative
CEA leveI greater than 10ng/ml in Dukes stage B or C
had decreased survival rates. In the group of patients with
elevated preoperative CEA and recurrence, this occurred
in the first year of follow up. Chu(7) and Groslin(3) aIso
reported that patients with eIevated CEA leveI had
recurrence after the first 6 months. Carpelan(12) found a
significant difference in survi vaI in patients with pre-
operative serum CEA above 5ng/mI and those with a lower
CEA leveI. Northover(\3) reported that the risk of recurrent
disease within two years of primary surgery was more
than double in those whose serum CEA was raised
preoperati vel y.
In this study we can conclude that preoperative CEA
higher than 10ng/ml was associated with poorer prognosis.
In these patients the recurrence wouId be more frequently
in the first year of follow up. The results from this series
are consistent with several published works. Although the
information provided by the tumor stage is still the most
valuable prognostic variable today, the preoperative
elevated CEA leveI provides additional information on the
prospects for survival, suggesting a more aggressive tumor
and probabIy identifying a subgroup of patients for adjuvant
therapy.
Table 4
Sensitivity(S), specificity(E), positive predictive value (PPV) and negative predictive value (NPV)
s= Nº of patients with recurrence and preoperative CEA > 5
Nº of patients with recurrence
E= Nº of patients without recurrence and preoperative CEA <5
Nº patients without recurrence
PPV= Nºof patients with elevated CEA and recurrence
Nº of patients with elevated CEA
NPV= Nº of patients with normal CEA and without recurrence
patients with normal CEA
s= .1.Q=50010
32
E= .41 =80,4°10
51
VPP=.1.Q =61 ,5°10
26
VPN= ~=72°10
57
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RESUMO
Introdução: O antígeno carcinoembrionário, CEA é o marcador tumoral mais usado em pacientes com câncer colorretal,
principalmente no acompanhamento clinico após ressecção cirúrgica do tumor. Níveis .séricos elevados de. CEA no pré-
operatório são frequentemente associados, em alguns estudos, a pior prognóstico. Objetivo: Comparar os níveis séricos de
CEA no pré-operatório e a frequência da recorrência no acompanhamento clinico. Material e Métodos: Oitenta e três pacientes
com câncer colorretal estadiados em Dukes A, B, e C foram avaliados retrospectivamente. Os pacientesforam acompanhados,
por no mínimo dois anos ou até o óbito. O CEA sérico foi determinado por Elisa (Sorine Biomédicas, valor normal 0-5 ng/ml).
Resultados: A recorrência foi observada em 32 pacientes (38.5%), sendo 13 pacientes Dukes B e 19 Dukes C. Setenta e
cinco por cento dos pacientes com CEA maior que 1Ong/ml apresentaram recorrência e oitenta por cento dos pacientes sem
recorrência tinham níveis séricos de CEA dentro do valor de normalidade. Nos pacientes .comCEA elevado no pré-operatório
e que desenvolveram recorrência, esta ocorreu no primeiro ano de acompanhamento em 56% dos pacientes. Dezesseis
pacientes foram a óbito durante o acompanhamento, 11 destes tinham CEA sérico aumentado no pré-operatório. Conclusão:
Embora, o estadiamento clinico seja a variável mais usada na avaliação do prognóstico, os valores de CEA no pré-operatório
podem fornecer algumas informações adicionais sobre o prognóstico do doente.
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